Bladder Sparing Regimens for Muscle Invasive Disease: Should We Be Doing this More?

Peter Black, MD, FACS, FRCSC, Khosrowshahi Family Chair and Professor in the Department of Urologic Sciences at the University of British Columbia (UBC) in Vancouver, discusses the merits of radiation-based, bladder-sparing therapies for muscle-invasive bladder cancer (MIBC). Dr. Black advises practitioners to discuss trimodal (TMT) as an option for patients with MIBC, consider neoadjuvant chemotherapy in patients planning to undergo TMT, consider alternative chemotherapy in cisplatin-ineligible patients, and remember the importance of shared decision-making.